Cargando…

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab

BACKGROUND: Targeted therapies directed at commonly overexpressed pathways in melanoma have clinical activity in numerous trials. Little is known about how these therapies influence microRNA (miRNA) expression, particularly with combination regimens. Knowledge of miRNAs altered with treatment may co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagenseller, Aubrey G, Shada, Amber, D’Auria, Kevin M, Murphy, Cheryl, Sun, Dandan, Molhoek, Kerrington R, Papin, Jason A, Dutta, Anindya, Slingluff Jr, Craig L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853033/ https://www.ncbi.nlm.nih.gov/pubmed/24047116 http://dx.doi.org/10.1186/1479-5876-11-218

Ejemplares similares

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
por: Molhoek, Kerrington R, et al.
Publicado: (2005)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
por: Jobard, Elodie, et al.
Publicado: (2015)

A novel method of screening combinations of angiostatics identifies bevacizumab and temsirolimus as synergistic inhibitors of glioma-induced angiogenesis
por: Dorrell, Michael I., et al.
Publicado: (2021)

Evaluating the activity of temsirolimus in neuroendocrine cancer
por: O'Donnell, P H, et al.
Publicado: (2007)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
por: Liu, Xiaochun, et al.
Publicado: (2016)

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer
por: Duran, I, et al.
Publicado: (2007)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
por: Kaley, Thomas J., et al.
Publicado: (2020)

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
por: Rangwala, Reshma, et al.
Publicado: (2014)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
por: Hadoux, Julien, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
por: Venugopal, Balaji, et al.
Publicado: (2013)

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
por: Chang, Hsuen-Wen, et al.
Publicado: (2018)

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
por: Afshar, Mehran, et al.
Publicado: (2014)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
por: Gabriel, Diana, et al.
Publicado: (2016)

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
por: Wang, Li, et al.
Publicado: (2010)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
por: Verschraegen, Claire F., et al.
Publicado: (2013)

Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus
por: Briggs, Joseph W., et al.
Publicado: (2017)

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2019)

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
por: Park, Inkeun, et al.
Publicado: (2019)

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
por: Wang-Gillam, Andrea, et al.
Publicado: (2014)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
por: Duran, I, et al.
Publicado: (2006)

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer
por: Zardavas, Dimitrios, et al.
Publicado: (2011)

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
por: Pulido, Marina, et al.
Publicado: (2018)

A case of delayed exacerbation of interstitial lung disease after discontinuation of temsirolimus
por: Matsuki, Rei, et al.
Publicado: (2017)

Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)
por: Belkacemi, Louiza, et al.
Publicado: (2022)

Antibody response to melanoma helper-peptide vaccine correlates with survival
por: Olson, Walter C, et al.
Publicado: (2013)

Bevacizumab treatment of meningeal melanoma metastases
por: Simonsen, Trude G., et al.
Publicado: (2020)

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
por: Yang, S, et al.
Publicado: (2010)

Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report
por: JURADO, JOSÉ MIGUEL, et al.
Publicado: (2013)

Metastatic clear cell renal carcinoma – an unusual response to Temsirolimus in second line therapy
por: Stanculeanu, DL, et al.
Publicado: (2016)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues
por: Kwak, Minyoung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bb2oeeoc9pbsh97j025p83kule